B4GALT3

Across TCGA pan-cancer cohorts, B4GALT3 Mutation is linked to patient survival in 8 of 34 cancer types, making it a survival-associated B4GALT3 data layer compared with 24 for mass-spec protein and 3 for mass-spec protein.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher B4GALT3 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated B4GALT3 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

HNSC, MESO, and SKCM are the cancer types where B4GALT3 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Median	All	0.002	0.768	<.001	48	view →
MESO	OS	Median	III,IV	0.098	0.579	.001	36	view →
SKCM	OS	Median	All	0.230	0.781	.004	24	view →
BLCA	OS	Median	IV	0.052	0.590	<.001	18	view →
ESCA	DFS	Median	All	0.080	0.533	<.001	18	view →
LUSC	OS	Median	II,III,IV	0.273	0.742	.028	9	view →
UCEC	DFS	Median	All	0.958	0.628	.035	6	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →

Pink = unfavorable, green = favorable. Showing the 8 strongest of 8 lineages.

B4GALT3–HNSC (OS)

Open the HNSC breakdown →